Dutch biotechnology company Crucell N.V. has signed a PER.C6 research license agreement with Edwards Lifesciences Corporation.

The non-exclusive agreement allows Edwards to use the PER.C6 cell line for research and development of gene therapeutics based on adenoviral vectors. Under the terms of the agreement, Crucell has also granted Edwards access to technical and regulatory support. Financial details were not disclosed.

Edwards Lifesciences is a global leader in products and technologies to treat advanced cardiovascular disease and is the number-one heart valve company in the world. Headquartered in Irvine, California, Edwards focuses on specific cardiovascular opportunities including heart valve disease, peripheral vascular disease and critical care technologies.